China's Biotech Licensing Boom Is Reaching the Income Statement. Is That Sustainable?

China's biotech licensing boom is increasingly visible in corporate earnings. For some companies, licensing has become a major source of revenue growth, helping offset pressure in their domestic pharmaceutical businesses.

But as these payments become more significant, investors face a different question: Are Chinese biotech companies building sustainable earnings, or bringing forward value from drugs they might otherwise commercialize themselves?

The latest financial results suggest that both are happening, with important differences between companies.

Hengrui: Licensing is driving earnings growth

Hengrui Pharma reported RMB24.41 billion in revenue for the first nine months of 2026, up 5.26% year-over-year. Net profit increased 20.38% to RMB6.92 billion, while licensing revenue reached RMB2.78 billion, representing 11.4% of total revenue.

The third quarter reveals how much licensing contributed.

Based on Hengrui's interim and nine-month disclosures, Q3 licensing revenue increased from approximately RMB130 million in 2025 to RMB1.36 billion in 2026. This increase accounted for roughly 80% of the company's year-over-year quarterly revenue growth.

Excluding licensing, Q3 revenue grew approximately 4.1%, compared with reported growth of 20.6%.

Hengrui's domestic business is not stagnant. Innovative drug sales increased 17.05% during the first nine months, led partly by non-oncology products. But generic drug sales declined 16.41%, leaving overall product sales growth at just 2.52%.

Licensing is therefore providing an important second source of growth while Hengrui transitions away from its traditional generic-drug business.

The quarterly volatility is equally revealing. Licensing revenue declined 28.6% year-over-year in H1 2026, before rebounding sharply in Q3. Even a company with multiple international partnerships can experience substantial fluctuations in recognized licensing income. [1,2]

The same licensing boom, different financial realities

Other Chinese pharmaceutical companies show similar contributions from licensing, but with different underlying businesses.

CompanyPeriodLicensing revenueReported revenue growthGrowth excluding licensingHengrui9M 2026RMB2.78B (11.4%)+5.3%+2.7%3SBioH1 2026RMB852M (18.8%)+3.9%−15.6%Sino BiopharmH1 2026RMB975M (5.0%)+10.6%+5.4%AkesoH1 2026RMB2.5M (0.1%)+27.9%+28.7%

Source: Company financial disclosures. Growth excluding licensing is calculated by subtracting licensing revenue from both the current and prior-year periods. It is not an adjusted profit measure. Reporting periods differ. [1–5]

At 3SBio, RMB852 million in licensing revenue, mainly associated with its Pfizer collaboration, helped offset a 19.3% decline in biopharmaceutical product sales. Without licensing, total revenue would have fallen approximately 15.6%. [3]

At Sino Biopharmaceutical, licensing revenue increased from RMB44 million to RMB975 million in H1 2026, accounting for roughly half of the company's total revenue increase. Its innovative drug sales also expanded, indicating a more balanced contribution from licensing and commercialization. [4]

Akeso presents a contrasting model. Its H1 2026 revenue growth came almost entirely from commercial drug sales, which increased 28.7%. Yet the company still reported a net loss of RMB447 million. Lower dependence on licensing does not automatically mean stronger profitability. [5]

These differences matter because a licensing-driven recovery in reported revenue should not necessarily be valued the same way as sustained growth in pharmaceutical sales.

Licensing is valuable. But what kind of value does it create?

The distinction between deal value, cash receipts and recognized revenue is important, but accounting alone does not explain the economics.

In the first nine months of 2026, Hengrui received RMB4.34 billion in licensing-related cash while recognizing RMB2.78 billion in licensing revenue. Cash receipts were equivalent to approximately 61% of its RMB7.15 billion in total R&D investment during the period. [1]

That comparison illustrates licensing's strategic importance: proceeds from international partnerships can finance substantial additional research, reduce reliance on external capital and allow companies to develop more assets.

This creates a potentially attractive cycle: develop assets, license selected rights, reinvest the proceeds, and generate the next pipeline.

The question is whether the next generation of assets can continually replace those already licensed.

Unlike recurring product sales, licensing income is often concentrated around upfront payments and development milestones. A company may consistently generate valuable partnerships without producing stable earnings from one quarter to the next.

There is also an economic trade-off.

Hengrui's agreement with Bristol Myers Squibb carried a headline potential value of approximately US$15.2 billion, but only US$600 million was upfront. Much of the remaining value depends on future milestones and options. Hengrui also retained certain territorial rights, potential royalties and opportunities to participate in selected programs. [6]

The central question is not simply how large the upfront payment is, but whether the proceeds and retained future economics adequately compensate for the rights and potential upside transferred.

Licensing early can reduce clinical and commercial risk, particularly when a partner has stronger global capabilities. Licensing too broadly or too cheaply, however, could limit the value a company captures if its assets eventually become successful global medicines.

Neither choice is inherently superior. The answer depends on development costs, probability of success, available capital and the company's ability to commercialize internationally.

What happens over the next two to three years?

I expect licensing to remain an important source of financing and earnings for leading Chinese biotech companies through 2027–2029. But I do not expect licensing-driven profits to grow smoothly.

Three developments are worth watching.

First, earnings growth may increasingly diverge from underlying pharmaceutical sales. Companies can report strong profitability during periods of licensing recognition even when their existing product portfolios grow slowly. Investors will need to distinguish a genuinely expanding commercial business from one benefiting from a particularly strong licensing period.

Second, repeatability will matter more than individual deal size. The strongest licensing businesses will be those capable of continuously generating competitive assets across multiple programs and development stages. A pipeline that produces one exceptional transaction is valuable; a discovery engine that repeatedly attracts international partners may deserve a more durable valuation premium. But that capability must be demonstrated over successive development cycles.

Third, royalty income will become an increasingly important test of long-term value creation. Much of today's licensing activity involves early-stage assets. Meaningful commercial royalties may still be years away and remain conditional on clinical success. Until those products advance, companies will depend primarily on additional transactions and milestones rather than established overseas product sales.

This suggests a possible change in how investors value Chinese biotech companies.

The market has already rewarded the ability to secure international partnerships. Over time, it may place greater weight on the quality of those agreements: how much upfront capital is secured, which programs advance, whether development milestones are achieved, how much commercial upside is retained, and whether new assets continue to emerge.

For biotech management teams, the challenge is similar. Maximizing the number or headline value of licensing deals is not necessarily the same as maximizing long-term shareholder value.

China's licensing boom has demonstrated that its pharmaceutical innovation can command international demand. The next test is whether companies can turn that demand into a repeatable, economically attractive business—without becoming dependent on continually selling the next promising asset to support today's earnings.

References

  1. Hengrui Pharma — Third Quarterly Report 2026, October 27, 2026

  2. Hengrui Pharma — Interim Report 2026, August 19, 2026

  3. 3SBio — Interim Results Announcement, August 20, 2026

  4. Sino Biopharmaceutical — Interim Results 2026, August 19, 2026

  5. Akeso — Interim Report 2026, September 30, 2026

  6. Bristol Myers Squibb — Strategic Collaboration with Hengrui Pharma, May 12, 2026

Previous
Previous

Globalization vs Deglobalization

Next
Next

China's Biotech Financing Was Already Changing. What Will COINS Add?